Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wake Forest University Health Sciences
With
National Cancer Institute (NCI)
Primary Objective(s):
* To assess hypoxia in primary prostate tumors by magnetic resonance imaging.
* To correlate hypoxic score with disease aggressiveness (proliferation biomarkers' expression).
Secondary Objective(s):
* To correlate hypoxic score with ExoHypoxic concentration in plasma of same patient.
* To correlate hypoxic score with fatty acid synthase (FASN) expression.
Age
40–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
The minimum age for this study is men 40 years and older. Prostate cancer mainly affects men over the age of 40.
Patients with Caucasian and African American race
Patients with pathology-proven prostate cancer (Gleason 6 or higher)
Patients who have not yet undergone therapy (systemic drugs, radiation, or prostatectomy)
Patients who will have a radical prostatectomy as standard of care.
Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
You may not be if
Patients who have already received some form of treatment or are not planning to undergo radical prostatectomy for treatment.
Patients with any other cancer along with prostate cancer.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Clareo Health | Characterize Tumor Hypoxia by Magnetic Resonance Imaging
